Evolus rises on FDA nod for anti-wrinkle gels

Evolus

13/02/2025 19:22

** Cosmetic drugmaker Evolus' shares  EOLS.O  rise 6.4% to
$15.10  
    ** Company says the U.S. FDA approved its two new
anti-wrinkle gels, Evolysee Form and Evolysee smooth, that can
improve the appearance of the face by restoring volume 
    ** Adds that the approval was based on a head-to-head study,
where both the gels met the main goal of non-inferiority when
compared with Switzerland-based Galderma's  GALD.S  Restylane-L
    ** EOLS plans to launch both gels in the U.S. in the second
quarter of 2025
    ** Stock fell 3.9% in the last 12 months 

 (Reporting by Padmanabhan Ananthan)
 ((Padmanabhan.Ananthan@thomsonreuters.com))